Arsenic trioxide and all-trans-retinoic acid selectively exert synergistic cytotoxicity against FLT3-ITD AML cells via co-inhibition of FLT3 signaling pathways

References

• Puumala SE, Ross JA, Aplenc R, et al. Epidemiology of childhood acute myeloid leukemia. Pediatr Blood Cancer. 2013;60:728–733.
   PubMed Web of Science ®Google Scholar
• Cornell RF, Palmer J. Adult acute leukemia. Dis Mon. 2012;58:219–238.
   PubMed Web of Science ®Google Scholar
• Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3:650–665.
   PubMed Web of Science ®Google Scholar
• Yanada M, Matsuo K, Suzuki T, et al. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia. 2005;19:1345–1349.
   PubMed Web of Science ®Google Scholar
• Takahashi S. Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. J Hematol Oncol. 2011;4:13.
   PubMed Web of Science ®Google Scholar
• Annesley CE, Brown P. The biology and targeting of FLT3 in pediatric leukemia. Front Oncol. 2014;4:263.
   PubMedGoogle Scholar
• Grunwald MR, Levis MJ. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. Int J Hematol. 2013;97:683–694.
   PubMed Web of Science ®Google Scholar
• Tashiro H, Shirasaki R, Oka Y, et al. FLT3 internal tandem duplication is associated with a high relapse rate and central nervous system involvement in acute promyelocytic leukemia cases: single institutional analysis. Eur J Haematol. 2011;86:272–273.
   PubMed Web of Science ®Google Scholar
• Lucena-Araujo AR, Kim HT, Jacomo RH, et al. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. Ann Hematol. 2014;93:2001–2010.
   PubMed Web of Science ®Google Scholar
• Breccia M, Loglisci G, Loglisci MG, et al. FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysis. Haematologica. 2013;98:e161–e163.
   PubMed Web of Science ®Google Scholar
• Iland H, Bradstock K, Seymour J, et al. Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica. 2012;97:227–234.
   PubMed Web of Science ®Google Scholar
• Gale RE, Hills R, Pizzey AR, et al. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood. 2005;106:3768–3776.
   PubMed Web of Science ®Google Scholar
• Barragan E, Montesinos P, Camos M, et al. Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. Haematologica. 2011;96:1470–1477.
   PubMed Web of Science ®Google Scholar
• Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2009;106:3342–3347.
   PubMed Web of Science ®Google Scholar
• Iland HJ, Bradstock K, Supple SG, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012;120:1570–1580.
   PubMed Web of Science ®Google Scholar
• Poire X, Moser BK, Gallagher RE, et al. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leuk Lymphoma. 2014;55:1523–1532.
   PubMed Web of Science ®Google Scholar
• Song X, Hu X, Lu S, et al. Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia. Eur J Haematol. 2014;93:54–62.
   PubMed Web of Science ®Google Scholar
• Molica M, Breccia M. FLT3-ITD in acute promyelocytic leukemia: clinical distinct profile but still controversial prognosis. Leuk Res. 2015;39:397–399.
   PubMed Web of Science ®Google Scholar
• Scholl S, Muller R, Clement JH, et al. ATRA can enhance apoptosis that is induced by Flt3 tyrosine kinase inhibition in Flt3-ITD positive cells. Leuk Res. 2006;30:633–642.
   PubMed Web of Science ®Google Scholar
• Chi HT, Ly BT, Vu HA, et al. Synergistic effect of all-trans retinoic acid in combination with protein kinase C 412 in FMS-like tyrosine kinase 3-mutated acute myeloid leukemia cells. Mol Med Rep. 2015;11:3969–3975.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Harigae H, Yokoyama H, et al. Synergistic effect of arsenic trioxide and flt3 inhibition on cells with flt3 internal tandem duplication. Int J Hematol. 2006;84:256–261.
   PubMed Web of Science ®Google Scholar
• Chevillard G, Paquet M, Blank V. Nfe2l3 (Nrf3) deficiency predisposes mice to T-cell lymphoblastic lymphoma. Blood. 2011;117:2005–2008.
   PubMed Web of Science ®Google Scholar
• Nakouzi NA, Cotteret S, Commo F, et al. Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer. Oncotarget. 2014;5:667–678.
   PubMed Web of Science ®Google Scholar
• Zheng M, Zhou Y, Yang X, et al. High GINS2 transcript level predicts poor prognosis and correlates with high histological grade and endocrine therapy resistance through mammary cancer stem cells in breast cancer patients. Breast Cancer Res Treat. 2014;148:423–436.
   PubMed Web of Science ®Google Scholar
• Luo BH, Xiong F, Wang JP, et al. Epidermal growth factor-like domain-containing protein 7 (EGFL7) enhances EGF receptor-AKT signaling, epithelial-mesenchymal transition, and metastasis of gastric cancer cells. PLoS One. 2014;9:e99922.
   PubMed Web of Science ®Google Scholar
• Wang YH, Israelsen WJ, Lee D, et al. Cell-state-specific metabolic dependency in hematopoiesis and leukemogenesis. Cell. 2014;158:1309–1323.
   PubMed Web of Science ®Google Scholar
• Sheng Z, Ma L, Sun JE, et al. BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription. Blood. 2011;118:2840–2848.
   PubMed Web of Science ®Google Scholar
• Rishi L, Hannon M, Salome M, et al. Regulation of Trib2 by an E2F1-C/EBPα feedback loop in AML cell proliferation. Blood. 2014;123:2389–2400.
   PubMed Web of Science ®Google Scholar
• Delgado MD, Leon J. Myc roles in hematopoiesis and leukemia. Genes Cancer. 2010;1:605–616.
   PubMedGoogle Scholar
• Stewart MJ, Litz-Jackson S, Burgess GS, et al. Role for E2F1 in p210 BCR-ABL downstream regulation of c-myc transcription initiation. Studies in murine myeloid cells. Leukemia. 1995;9:1499–1507.
   PubMed Web of Science ®Google Scholar
• Leone G, DeGregori J, Sears R, et al. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature. 1997;387:422–426.
   PubMed Web of Science ®Google Scholar
• Zhang S, Fukuda S, Lee Y, et al. Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling J Exp Med. 2000;192:719–728.
   PubMed Web of Science ®Google Scholar
• Sheng Z, Evans SK, Green MR. An activating transcription factor 5-mediated survival pathway as a target for cancer therapy? Oncotarget. 2010;1:457–460.
   PubMed Web of Science ®Google Scholar
• Emadi A, Sadowska M, Carter-Cooper B, et al. Perturbation of cellular oxidative state induced by dichloroacetate and arsenic trioxide for treatment of acute myeloid leukemia. Leuk Res. 2015;39:719–729.
   PubMed Web of Science ®Google Scholar
• Wetzler M, Brady MT, Tracy E, et al. Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation. Clin Cancer Res. 2006;12:6817–6825.
   PubMed Web of Science ®Google Scholar
• Fleckenstein DS, Uphoff CC, Drexler HG, et al. Detection of p53 gene mutations by single strand conformational polymorphism (SSCP) in human acute myeloid leukemia-derived cell lines. Leuk Res. 2002;26:207–214.
   PubMed Web of Science ®Google Scholar
• Hu M, Wang B, Qian D, et al. Interference with ATF5 function enhances the sensitivity of human pancreatic cancer cells to paclitaxel-induced apoptosis. Anticancer Res. 2012;32:4385–4394.
   PubMed Web of Science ®Google Scholar
• Chen A, Qian D, Wang B, et al. ATF5 is overexpressed in epithelial ovarian carcinomas and interference with its function increases apoptosis through the downregulation of Bcl-2 in SKOV-3 cells. Int J Gynecol Pathol. 2012;31:532–537.
   PubMed Web of Science ®Google Scholar
• Gho JW, Ip WK, Chan KY, et al. Re-expression of transcription factor ATF5 in hepatocellular carcinoma induces G2-M arrest. Cancer Res. 2008;68:6743–6751.
   PubMed Web of Science ®Google Scholar
• Martelli MP, Gionfriddo I, Mezzasoma F, et al. Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. Blood. 2015;125:3455–3465.
   PubMed Web of Science ®Google Scholar
• El HH, Dassouki Z, Berthier C, et al. Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. Blood. 2015;125:3447–3454.
   PubMed Web of Science ®Google Scholar